Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
JNJ Price Action
Last 7 days
-0.5%
Last 30 days
1.6%
Last 90 days
-1.3%
Trailing 12 Months
2.8%
JNJ Stock Price
JNJ RSI Chart
JNJ Valuation
JNJ Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
JNJ Fundamentals
JNJ Revenue
JNJ Earnings
JNJ Profitability
JNJ Investor Care
JNJ Alerts
The Good News
Johnson & Johnson (JNJ) delivered a solid Q1 with earnings of $2.77 per share and revenue of $21.89 billion, exceeding expectations, while also raising its full-year guidance to $91-$91.8 billion, demonstrating strong growth in its pharmaceutical and MedTech divisions. The stock has gained 7% year-to-date, and the company has increased its quarterly dividend to $1.30, marking the 63rd consecutive year of dividend increases, which emphasizes its commitment to shareholder returns. (Sources: Yahoo Finance)
The Bad News
Despite strong earnings, Johnson & Johnson (JNJ) is grappling with significant challenges, including a 34% drop in Stelara sales due to competition from biosimilars and a $400 million impact from tariffs affecting its medical device business. Furthermore, ongoing litigation, particularly concerning talc-related issues, poses additional risks that could hinder future growth. Analysts maintain mixed opinions, with Barclays lowering its price target amidst concerns over stock performance. (Sources: Markets Insider)
Revenue & Growth
Revenue Breakdown
As of: Mar 31, 2025
Innovative Medicine
| |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
| |||||||||||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 89.3B | 0 | 0 | 0 |
| 2024 | 85.6B | 86.6B | 87.7B | 88.8B |
| 2023 | 81.0B | 82.3B | 83.7B | 85.2B |
| 2022 | 76.3B | 73.2B | 69.8B | 80.0B |
| 2021 | 84.2B | 89.2B | 91.4B | 78.7B |
| 2020 | 82.7B | 80.5B | 80.9B | 82.6B |
| 2019 | 81.6B | 81.3B | 81.7B | 82.1B |
| 2018 | 78.7B | 80.7B | 81.4B | 81.6B |
| 2017 | 72.2B | 72.5B | 74.4B | 76.5B |
| 2016 | 70.2B | 70.9B | 71.6B | 71.9B |
| 2015 | 73.6B | 71.9B | 70.5B | 70.1B |
| 2014 | 71.9B | 73.5B | 74.4B | 74.3B |
| 2013 | 68.6B | 70.0B | 70.5B | 71.3B |
| 2012 | 65.0B | 64.9B | 65.9B | 67.2B |
| 2011 | 62.1B | 63.4B | 64.4B | 65.0B |
| 2010 | 62.5B | 62.6B | 62.5B | 61.6B |
| 2009 | 62.6B | 61.4B | 60.5B | 61.9B |
| 2008 | 0 | 62.0B | 62.9B | 63.7B |
| 2007 | 0 | 0 | 0 | 61.1B |
Get all data in R, Python etc through our Historical Stock Data APIs
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
| CEO | Mr. Joaquin Duato |
|---|---|
| WEBSITE | jnj.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers General |
| EMPLOYEES | 65535 |
